10 or 15 mg once weekly) vs Reduce to tirzepatide 5 mg once weekly vs Placebo for 52 weeks (randomized 3:3:2 at week 60) Primary outcome: Percent change in bodyweight from baseline to week 112 Results: Primary outcome (percent change in bodyweight at week 112): Tirzepatide MTD -21.9%, Tirzepatide 5 mg -16.6%, Placebo -9.9% (estimated treatment difference vs placebo -12.0% for MTD and -6.6% for 5 mg
Analyses using the Broad Institutes Connectivity Map suggest GHK may regulate more than 4,000 human genes, resetting aging-associated patterns toward profiles characteristic of younger tissue.23 In human plasma, GHK concentrations decline from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60a decline coinciding with the noticeable decrease in regenerative capacity that every aging athlete experiences firsthand
Kisli M, Sacmaci H
3c), as presented by Goldfeder et al
These factors may seem unrelated to peptide dosing, but they substantially impact outcomes
Gut infections can impact nutrient absorption, metabolism, mitochondrial health, and the immune system